The effect of crocin in multiple sclerosis patients

Phase 2

Conditions: Condition 1: Multiple sclerosis. Condition 2: Multiple sclerosis. Condition 3: Multiple sclerosis.
Other acute disseminated demyelination
Multiple sclerosis
Other demyelinating diseases of central nervous system

Registration Number: IRCT2016122013194N3

Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 40

Inclusion Criteria

inclusion criteria:Recently diagnosed relapsing-remitting MS patients; Patients between 20-40 years old exclusion criteria: Receiving corticosteroids before the study; Receiving immunomodulatory drugs such as interferons before the study; Diabetes; Underlying chronic illnesses including liver disease, kidney, lung and heart; Smoking; Pregnancy and lactation; Any rheumatologic disease or vasculitis; History of hypersensitivity to saffron

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Total antioxidant capacity of urine. Timepoint: Before and after intervention. Method of measurement: spectrophotometer TPTZ reagent in a 593 nm.;Catalase Enzyme. Timepoint: Before and after intervention. Method of measurement: According U / ml using Spectrophotometry.;Total antioxidant capacity of saliva. Timepoint: Before and after intervention. Method of measurement: According U / ml using Spectrophotometry.;Thiol groups of saliva. Timepoint: Before and after intervention. Method of measurement: According U / ml using Spectrophotometry.;Lipid peroxidation. Timepoint: Before and after intervention. Method of measurement: spectrophotometer TBA reagent in a 532 nm.;Thiol levels in urine. Timepoint: Before and after intervention. Method of measurement: HU method.

Secondary Outcome Measures